175

Angelina Mimoun

Transplacental delivery of maternal FVIII for induction of FVIII-specific immune tolerance

208

Nuno Graca

N-glycan shielded rhADAMTS13 for treatment of immune Thrombotic Thrombocytopenic Purpura

138

Laure De Waele

Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura

182

Cristina Olgasi

From coagulation to angiogenesis: possible role of FVIII in endothelial functionality

185

Marije Kat

Syntaxin 5 is Essential for Golgi Integrity, Weibel-Palade Body Biogenesis and Stimulus-Induced Von Willebrand Factor Secretion from Endothelial Cells

194

Suzan De Boer

Developing a model for studying Von Willebrand disease with hiPSC-derived endothelial cells

142

Michela Milani

Liver Gene Therapy with Lentiviral Vectors Corrects Hemophilia A in Mice and Achieves Normal-Range Factor VIII Activity in Non-Human Primates

187

Omid Seidizadeh

Genetic determination of enhanced von Willebrand factor clearance

190

Tom Arfman

PAD4-mediated citrullination of ADAMTS13 in sepsis and immune-mediated TTP

218

Viola Strijbis

Preclinical efficacy and safety assessment of a recombinant factor IX variant that functions independently of factor VIII in combination with current hemophilia A therapeutics

184

Maurice Swinkels

Differential release of VWF and VWF-propeptide from platelet alpha-granules

125

Marc Jacquemin

The specificity of the assay determines the measurement of FVIII antigen levels in patients with severe haemophilia A

200

Mariarosaria Miranda

Selection of immuno-dominant T cell epitopes from the repertoire of FVIII derived peptides presented on MHC class II

176

Mélissa Bou Jaoudeh

The IgG-degrading enzyme from Streptococcus pyogenes as a new tool for the elimination of factor VIII inhibitors

191

Syna Miri

IgG2 as hallmark of inhibitor persistence in PUPs: a longitudinal analysis along exposure to FVIII

197

Awital Bar Barroeta

Interaction of factor XI with ligands studied with novel anti-factor XI nanobodies

143

Gili Kenet

The safety and efficacy of N8-GP in previously untreated patients (PUPs) with severe haemophilia A: Interim results from the main and extension phases of pathfinder6

149

Omid Seidizadeh

Genetic characterization of von Willebrand disease type 2 in Milan Cohort patients

153

Paola Colpani

Evaluation of the different platelet-dependent von Willebrand factor activity assays capacity to assess the in vivo inhibitory effect of caplacizumab on the VWF-platelet interaction

160

Christoph Male

A post-hoc analysis of temporarily decreased incremental recovery (IR) observed in a subset of previously untreated patients (PUPs) with haemophilia A treated with N8-GP

161

Syna Miri

Inhibitor development upon switch from plasma-derived to recombinant FVIII in PUPs with severe haemophilia A: preliminary analysis of the PUP-SWITCH study

166

Carla Valsecchi

Functional transitory anti emicizumab antibody creating bleeding episodes

169

Yvonne Jongejan

Identification of small interfering RNAs for allele-selective silencing of murine von Willebrand factor

174

Tine Goedhart

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in hemophilia A?

192

Mira Türknetz

GEPHARD – the PUP cohort of the 'Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research' - a progress report

209

Anna Pagotto

The Extracellular Protease EpiP from S. aureus Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1

145

Samantha Pasca

Catridecacog in the treatment of an Italian population of patients with FXIII deficiency: from pharmacokinetics to clinical outcomes (The Italian rFXIII study)

167

Bas Calcoen

Measurement of von Willebrand factor levels via fiber optic-surface plasmon resonance

172

Gillian Walker

Exploring the role of Factor VIII as a potential player in cancer cells

177

Shermarke Hassan

D-dimer as a predictive marker for mortality in hospitalized COVID-19 patients

181

Eleni Gavriilaki

A combination of complement-related variants predicts severe COVID-19 with high sensitivity and specificity

189

Marie-Helene Andre-Bonnet

Evaluation of Health-related quality of life in patients with von Willebrand disease on long-term prophylaxis: WiSH-QoL intermediary results

196

Chava Kimchi-Sarfaty

Investigation of ADAMTS13-independent cleavage and regulation of von Willebrand Factor

217

Berardino Pollio

Real-world experience with emicizumab in an italian paediatric cohort: focus on PUPs and tolerized children

222

Tom Howard

Might Loss-of-Function FII-Variant-543R>L—a Major-Determinant of Mexican-American Coagulability—Contribute to the High-Risk of FVIII-Inhibitors in Hemophilia-Patients of this Ethnicity?

131

Hande Kizilocak

Safety of FEIBA and emicizumab (SAFE): Dose Escalation Study Evaluating the Safety of in vivo Administration of activated Prothrombin Complex Concentrate in Hemophilia A Patients on Emicizumab

135

Dario Balestra

Deep molecular mechanisms of F8 exon 19 variants and translational approaches in Hemophilia A

151

Ricardo Mesquita Camelo

Time from the inhibitor detection to the start of immune tolerance induction and the outcome of immune tolerance induction: results from the Brazilian Immune Tolerance (BrazIT) Study

168

Carla Valsecchi

Development of a new ELISA method for anti-FVIIa antibody measurement

199

Reyes-Ruiz Alejandra

Transplacental delivery of recombinant Fc-fused factor VIII (rFVIIIFc) in FVIII-deficient mice

137

György Sinkovits

Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients

152

Ricardo Mesquita Camelo

Cost-effectiveness analysis of the Brazilian Immune Tolerance Induction Protocol with prophylaxis with bypassing agents or emicizumab

155

Fatma Keklik Karadağ

FACTOR V DEFICIENCY AND DEEP VENOUS THROMBOSIS: A CASE REPORT

173

Eleni Gavriilaki

Elevated soluble C5b-9 as a rough marker of complement activation in complications of sickle cell disease

186

Desiree Coen Herak

A patient with FVIII inhibitors on emicizumab prophylaxis switching to immune tolerance induction – laboratory issues

198

Sonata Saulyte Trakymiene

Emicizumab for the Management of Children with Severe Hemophilia A: Experience from Hemophilia Centres in Lithuania

207

Jayson Tang

Confirmed safety profile of BAY 94-9027 prophylaxis for ≥5 Years: outcomes from the PROTECT VIII and PROTECT VIII Kids extension studies

211

Jan Ulrich Becker

Automatic segmentation of arteries, arterioles and glomeruli on kidney biopsies with thrombotic microangiopathies

130

Anna Kouraba

ACQUIRED HAEMOPHILIA: CLINICAL MANIFESTATIONS AND MANAGEMENT EXPERIENCE FROM A SINGLE CENTRE

136

Chiara Borsotti

Alteration of the intrinsic proliferation capability of haemophilic CD8 T cells

159

Alkistis Adramerina

OFF LABEL USE OF MULTIPLE AGENTS IN ORDER TO CONTROL BLEEDING EPISODES IN A BOY WITH WISKOTT-ALDRICH SYNDROME

193

Athina Dettoraki

Coagulation Disorders in Paediatric Patients Hospitalized due to SARS-CoV-2 Infection

201

Sofia Teixeira

HEAVY MENSTRUAL BLEEDING IN VON WILLEBRAND PATIENTS – THE REALITY OF A TERTIARY CARE HOSPITAL

215

Jasmeet Kaur

Coagulation profile and laboratory data in Covid 19 patients on chronic anticoagulation or antiplatelet therapy

156

Fatma Keklik Karadağ

RECURRENT INTRAVITREAL ANTI-VEGF TREATMENT IN HEMOPHILIA B PATIENT WITH OCULAR DEGENERATION

157

Fatma Keklik Karadağ

MANAGEMENT OF MAJOR SURGERY IN A PATIENT WITH TYPE 3 VON WILLEBRAND DISEASE WHO HAS LOW TITER INHIBITOR

163

Caterina Bosio

Words in hemophilia: a project for a better patient engagement

180

Louis Aledort

How can we better understand complications arising from FVIII substitute therapies?

203

Inês Machado

VON WILLEBRAND DISEASE TYPE 2B AND DDAVP. STILL A TREATMENT DRUG TO AVOID?

205

Diaan Gonçalves

Thrombosis in inherited hypofibrinogenemia: a case report

220

Paola Ranalli

A case of VITT (vaccine-induced immune thrombotic thrombocytopenia) without cerebral vein thrombosis post Vaxzevria vaccine exposure: clinical and laboratory diagnosis and favourable outcome

129

Anna Kouraba

EMICIZUMAB PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HAEMOPHLIA A INHIBITORS : EXPERIENCE FROM A GREEK HAEMOPHILIA CENTRE

132

Esther Mairal

CLINICAL EFFICACY AND SAFETY OF PLASMA-DERIVED VON WILLEBRAND FACTOR- FVIII COMPLEX CONCENTRATES, IN PATIENTS WITH VON WILLEBRAND DISEASE IN ITALY: STUDY DESIGN

179

Nataliya Shurko

THE STUDY OF THE EFFECT OF SUBSTANCES ARE USED IN THE PROCESS OF PURIRFICATION ON THE DETERMINATION OF FACTOR VIII ACTIVITY

204

Inês Machado

THE CHALLENGING MANAGEMENT OF PREGNANCY IN TYPE 3 VON WILLEBRAND DISEASE: LABOR, DELIVERY AND POSTPARTUM. A CASE REPORT

221

Alfadil Haroon

Massive haemothorax in hemophilia A patient with high factor VIII inhibitors treated successfully with high dose of factor VIII

154

Samin' Mohsenian

Application of the ISTH-BAT In Congenital Fibrinogen Disorders

171

Nataliya Shurko

PRIOR PLASMA FRACTIONATION: СHOICE OF THE METHOD PRECIPITATION AND SEARCH FOR RAW MATERIALS

202

Sofia Teixeira

IMMUNE THROMBOCYTOPENIAPURPURA (ITP) RELAPSE OR VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT).WHAT CAN WE CONCLUDE FROM A CASE REPORT?